In HCC, m6A regulators such as HNRNPC have emerged as key prognostic indicators and potential therapeutic targets, especially in the context of immunotherapy, underscoring the importance of m6A‐regulated patterns in stratifying HCC patients for personalized treatment [66]. The gene discussed is HNRNPC; the disease is hepatocellular carcinoma.